About: Network-based Drug Repurposing for Human Coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Network-based Drug Repurposing for Human Coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Network-based Drug Repurposing for Human Coronavirus
Creator	Martin, William Cheng, Feixiong Hou, Yuan Huang, Yin Shen, Jiayu Zhou, Yadi
source	MedRxiv
abstract	Human Coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle east respiratory syndrome coronavirus (MERS-CoV), and 2019 novel coronavirus (2019-nCoV), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV. Drug repurposing, represented as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV has the highest nucleotide sequence identity with SARS-CoV (79.7%) among the six other known pathogenic HCoVs. Specifically, the envelope and nucleocapsid proteins of 2019-nCoV are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and known HCoV-host interactions in the human protein-protein interactome, we computationally identified 135 putative repurposable drugs for the potential prevention and treatment of HCoVs. In addition, we prioritized 16 potential anti-HCoV repurposable drugs (including melatonin, mercaptopurine, and sirolimus) that were further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. Finally, we showcased three potential drug combinations (including sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the Complementary Exposure pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human protein-protein interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations toward future clinical trials for HCoVs.
has issue date	2020-02-05(xsd:dateTime)
bibo:doi	10.1101/2020.02.03.20020263
has license	medrxiv
sha1sum (hex)	21100aba41a4bfb48d7dc37f1bf5dbb38bf3867a
schema:url	https://doi.org/10.1101/2020.02.03.20020263
resource representing a document's title	Network-based Drug Repurposing for Human Coronavirus
resource representing a document's body	covid:21100aba41a4bfb48d7dc37f1bf5dbb38bf3867a#body_text
is schema:about of	named entity 'nucleotide sequence' named entity 'evolutionarily conserved' named entity 'de novo' named entity 'drug discovery' named entity 'platform' named entity 'effective' named entity 'identity' named entity 'NETWORK' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' covid:arg/21100aba41a4bfb48d7dc37f1bf5dbb38bf3867a named entity 'NETWORK' named entity 'METHODOLOGY' named entity 'SYSTEMS' named entity 'CORONAVIRUSES' named entity 'KNOWN' named entity 'INTERACTOME' named entity 'BASED' named entity 'PRESENT' named entity 'HOST' named entity 'CONSERVED' named entity 'COST' named entity 'REDUCE' named entity 'SEQUENCE' named entity 'BASED' named entity 'DRUG' named entity 'MORBIDITY AND MORTALITY' named entity 'SEQUENCE IDENTITY' named entity 'DRUGS TARGETING' named entity 'SARS-COV' named entity 'INCLUDING' named entity 'EFFECTIVE' named entity 'IDENTITIES' named entity 'HIGHEST' named entity 'DRUGS' named entity 'HUMAN PROTEIN' named entity 'COMPARED' named entity 'PLATFORM' named entity 'PATHOGENIC' named entity 'EPIDEMICS' named entity '2019 NOVEL CORONAVIRUS' named entity 'STRATEGY' named entity 'DRUG' named entity 'MEDICINE' named entity 'GLOBAL' named entity 'CURRENTLY' named entity 'SHORTEN' named entity 'STUDY' named entity 'PROTEIN-PROTEIN INTERACTION NETWORK' named entity 'DRUG DISCOVERY' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS' named entity 'LEAD' named entity 'REVEAL' named entity 'ENVELOPE' named entity 'NUCLEOTIDE SEQUENCE' named entity 'NUCLEOCAPSID PROTEINS' named entity 'TIME' named entity 'DE NOVO' named entity 'HIGH' named entity 'HUMAN CORONAVIRUS' named entity 'HUMAN' named entity 'ANTIVIRAL DRUG' named entity 'REGIONS' named entity 'DRUG TARGETS' named entity 'WHOLE GENOMES' named entity 'PHARMACOLOGY' named entity 'interactome' named entity 'coronavirus' named entity '2019-nCoV' named entity 'drugs' named entity 'cost' named entity 'Phylogenetic analyses' named entity 'pathogenic' named entity '2019-nCoV' named entity 'Repurposing' named entity 'coronavirus' named entity 'nucleotide sequence' named entity 'SARS-CoV' named entity 'severe acute respiratory syndrome coronavirus' named entity 'sequence identities' named entity 'protein-protein interaction network'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software